gria1-protein

Migration, Crosslink

📖

gria1-protein

active

wiki page Created: 2026-04-02T07:19:07 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-proteins-gria1-protein

📖 Wiki Page

protein2371 wordssynced 2026-04-02

GRIA1 Protein (AMPA Receptor Subunit 1)

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">gria1-protein</th>
</tr>
<tr>
<td class="label">Approach</td>
<td>Agent/Strategy</td>
</tr>
<tr>
<td class="label">AMPA Antagonists</td>
<td>Perampanel</td>
</tr>
<tr>
<td class="label">AMPA Modulators</td>
<td>CX-516 (Ampalex)</td>
</tr>
<tr>
<td class="label">Ampakines</td>
<td>CX-717, IDRA-21</td>
</tr>
<tr>
<td class="label">Gene Therapy</td>
<td>AAV-GRIA1</td>
</tr>
<tr>
<td class="label">Kinase Inhibitors</td>
<td>CaMKII inhibitors</td>
</tr>
<tr>
<td class="label">Zinc Modulation</td>
<td>Zinc compounds</td>
</tr>
<tr>
<td class="label">Interaction Partner</td>
<td>Function</td>
</tr>
<tr>
<td class="label">[GRIA2](/proteins/gria2)</td>
<td>Subunit assembly</td>
</tr>
<tr>
<td class="label">[GRIA3](/proteins/gria3)</td>
<td>Subunit assembly</td>
</tr>
<tr>
<td class="label">[PSD-95](/proteins/dlg4)</td>
<td>Synaptic anchoring</td>
</tr>
<tr>
<td class="label">[SAP97](/genes/sap97)</td>
<td>Synaptic targeting</td>
</tr>
<tr>
<td class="label">[GRIP1](/genes/grip1)</td>
<td>Receptor trafficking</td>
</tr>
<tr>
<td class="label">[PICK1](/genes/pick1)</td>
<td>Receptor internalization</td>
</tr>
<tr>
<td class="label">[Stargazin](/genes/cacnb4)</td>
<td>Trafficking/chaperone</td>
</tr>
<tr>
<td class="label">[CaMKII](/genes/camk2a)</td>
<td>Phosphorylat

...

GRIA1 Protein (AMPA Receptor Subunit 1)

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">gria1-protein</th>
</tr>
<tr>
<td class="label">Approach</td>
<td>Agent/Strategy</td>
</tr>
<tr>
<td class="label">AMPA Antagonists</td>
<td>Perampanel</td>
</tr>
<tr>
<td class="label">AMPA Modulators</td>
<td>CX-516 (Ampalex)</td>
</tr>
<tr>
<td class="label">Ampakines</td>
<td>CX-717, IDRA-21</td>
</tr>
<tr>
<td class="label">Gene Therapy</td>
<td>AAV-GRIA1</td>
</tr>
<tr>
<td class="label">Kinase Inhibitors</td>
<td>CaMKII inhibitors</td>
</tr>
<tr>
<td class="label">Zinc Modulation</td>
<td>Zinc compounds</td>
</tr>
<tr>
<td class="label">Interaction Partner</td>
<td>Function</td>
</tr>
<tr>
<td class="label">[GRIA2](/proteins/gria2)</td>
<td>Subunit assembly</td>
</tr>
<tr>
<td class="label">[GRIA3](/proteins/gria3)</td>
<td>Subunit assembly</td>
</tr>
<tr>
<td class="label">[PSD-95](/proteins/dlg4)</td>
<td>Synaptic anchoring</td>
</tr>
<tr>
<td class="label">[SAP97](/genes/sap97)</td>
<td>Synaptic targeting</td>
</tr>
<tr>
<td class="label">[GRIP1](/genes/grip1)</td>
<td>Receptor trafficking</td>
</tr>
<tr>
<td class="label">[PICK1](/genes/pick1)</td>
<td>Receptor internalization</td>
</tr>
<tr>
<td class="label">[Stargazin](/genes/cacnb4)</td>
<td>Trafficking/chaperone</td>
</tr>
<tr>
<td class="label">[CaMKII](/genes/camk2a)</td>
<td>Phosphorylation</td>
</tr>
<tr>
<td class="label">[PKC](/genes/prkcb)</td>
<td>Phosphorylation</td>
</tr>
<tr>
<td class="label">[RhoA](/genes/rhoa)</td>
<td>Cytoskeletal dynamics</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/huntington" style="color:#ef9a9a">Huntington</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a>, <a href="/wiki/parkinson" style="color:#ef9a9a">Parkinson</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">58 edges</a></td>
</tr>
</table>

Introduction

The GRIA1 protein (GluA1) is a critical subunit of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) type glutamate receptor, the primary mediator of fast excitatory synaptic transmission in the mammalian brain. AMPA receptors containing the GluA1 subunit play essential roles in synaptic plasticity, learning, and memory, and their dysfunction is increasingly recognized as a key contributor to the pathogenesis of neurodegenerative diseases including [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), and [amyotrophic lateral sclerosis](/diseases/amyotrophic-lateral-sclerosis-als). [@traynelis2010]

This page provides comprehensive information about GRIA1 protein structure, its normal physiological functions in the nervous system, its role in disease processes, and emerging therapeutic strategies targeting this receptor.

:: infobox infobox-protein
!Protein Name | Glutamate Ionotropic Receptor AMPA Type Subunit 1 (GRIA1)
!Gene | [GRIA1](/genes/gria1)
!UniProt ID | [P42262](https://www.uniprot.org/uniprot/P42262)
!PDB Structure | 4G5F, 5LMP, 6XJN, 7MLX
!Molecular Weight | ~103 kDa (906 amino acids)
!Subcellular Localization | Postsynaptic membrane, dendritic spines
!Protein Family | Ionotropic glutamate receptors, AMPA receptor family
!Brain Expression | High in hippocampus, cortex, striatum, cerebellum
!

Structure

GRIA1 (GluA1) is an AMPA receptor subunit with a characteristic ion channel architecture consisting of four distinct domains that work in concert to mediate rapid synaptic signaling. [@twomey2017]

Domain Architecture

N-terminal domain (NTD) (aa 1-380): The extracellular NTD controls subunit assembly, receptor trafficking, and allosteric modulation. It forms dimers in the receptor assembly process and influences gating properties through inter-subunit interactions. The NTD also mediates interactions with auxiliary subunits (e.g., stargazin, GRIP, PICK1) that regulate receptor trafficking and localization. [@greger2017]

Ligand-binding domain (LBD) (aa 400-506, 632-790): The bi-lobed LBD binds glutamate (the endogenous agonist) and forms a "clam-shell" structure that undergoes conformational changes upon agonist binding. The LBD contains the binding sites for:

Glutamate (agonist)
AMPA (synthetic agonist)
CNQX, NBQX (competitive antagonists)
Aniracetam, cyclothiazide (positive allosteric modulators)

Transmembrane domain (TMD) (aa 807-830): Four transmembrane helices (M1-M4) form the ion channel pore. The M2 helix forms the channel pore lining, determining ion selectivity. AMPA receptors are permeable to Na+ and K+; Ca2+ permeability depends on the presence of the GluA2 subunit (RNA-edited at the Q/R site).

C-terminal tail (CTD) (aa 831-906): The intracellular CTD contains PDZ-binding motifs (SXV) that interact with PSD-95, SAP97, and other PDZ domain proteins. These interactions regulate:

Synaptic targeting and anchoring
Activity-dependent trafficking
Receptor internalization
Signal transduction

Quaternary Structure

AMPA receptors are tetramers, typically composed of combinations of GRIA1-4 subunits. The most common configurations include:

GluA1/2 heterotetramers: ~80% of synaptic AMPA receptors in the hippocampus
GluA1/2/3 heterotetramers: Common in cortical neurons
GluA1 homomers: Rare in vivo, but can form calcium-permeable receptors

The subunit composition determines the receptor's functional properties, including:

Calcium permeability: GluA1 homomers (without GluA2) are calcium-permeable
Kinetic properties: Deactivation and desensitization rates vary by subunit composition
Trafficking behavior: GluA1-containing receptors require activity for insertion

Normal Function

AMPA receptors containing the GRIA1 subunit mediate fast excitatory synaptic transmission and are fundamental to synaptic plasticity, the cellular basis of learning and memory. [@huganir2013]

Synaptic Transmission

Fast Excitatory Neurotransmission: AMPA receptors mediate the majority of rapid excitatory signaling in the central nervous system (CNS). Upon glutamate release from the presynaptic terminal, GluA1-containing receptors conduct Na+ ions, depolarizing the postsynaptic membrane within milliseconds. [@traynelis2010]

Integration of Synaptic Inputs: Multiple excitatory synapses converge on individual neurons, and AMPA receptor-mediated currents integrate these inputs to determine neuronal firing patterns.

Synaptic Plasticity

Long-term Potentiation (LTP): Activity-dependent strengthening of synaptic connections. GluA1 trafficking is essential for LTP:

NMDA receptor activation triggers Ca2+ influx
CaMKII phosphorylates GluA1 at Ser831
Phosphorylation enhances single-channel conductance
GluA1-containing receptors are inserted into the synapse
LTP is impaired in GluA1 knockout mice

Long-term Depression (LTD): Activity-dependent weakening of synapses. GluA1-containing receptors are removed from synapses during LTD through clathrin-mediated endocytosis. [@diering2017]

Calcium Signaling

Calcium-Permeable AMPA Receptors: GluA1 homomers (lacking edited GluA2) are calcium-permeable. These receptors are enriched in specific neuronal populations and during certain developmental stages.

Calcium-Triggered Signaling: Calcium influx through GluA1-containing receptors can activate intracellular signaling cascades, including:

Calmodulin activation
CaMKII signaling
Calcineurin (PP2B) signaling

Learning and Memory

The GluA1 subunit is critical for [hippocampus](/brain-regions/hippocampus)-dependent learning and memory. Studies demonstrate:

GluA1 knockout mice show specific learning deficits
GluA1-deficient mice fail to acquire spatial memory tasks
LTP deficits correlate with memory impairments

Role in Disease

Alzheimer's Disease

Alzheimer's disease (AD) is characterized by progressive synaptic dysfunction and loss, with AMPA receptor pathology emerging as a key mechanism. [@chen2014]

Amyloid-Beta Effects

[Amyloid-beta](/proteins/amyloid-beta) (Aβ) oligomers, the most synaptotoxic species in AD, directly target AMPA receptors:

Reduced Surface Expression: Aβ oligomers reduce AMPA receptor surface expression through:

Accelerated receptor internalization
Impaired recycling
Disruption of synaptic anchoring

Synaptic Targeting: Aβ oligomers preferentially target synaptic AMPA receptors, disrupting excitatory synaptic transmission before causing overt neuronal loss. [@zhao2018]

LTP Impairment: Aβ oligomers impair NMDA receptor-dependent LTP, partially through effects on AMPA receptor trafficking. [@palop2011]

Tau Pathology Effects

[Tau](/proteins/tau) pathology, the second hallmark of AD, also disrupts AMPA receptor function: [@liu2019]

Trafficking Impairment: Pathological tau reduces AMPA receptor trafficking to synapses through:

Altered scaffolding protein interactions
Disruption of cytoskeletal dynamics
Impaired recycling pathways

Cognitive Correlation: Synaptic AMPA receptor loss correlates with cognitive impairment in AD patients. [@tang2019]

Therapeutic Implications

Understanding Aβ-tau-AMPA receptor interactions has revealed potential therapeutic targets:

AMPA modulators: Enhance receptor function to compensate for loss
Prevent internalization: Stabilize synaptic receptors
Calcium homeostasis: Protect against excitotoxic calcium influx

Parkinson's Disease

While traditionally associated with dopaminergic dysfunction, Parkinson's disease (PD) involves widespread glutamatergic signaling alterations: [@liu2020]

Striatal Dysfunction: Altered AMPA receptor expression in the striatum contributes to motor control deficits.

Excitotoxicity: Excessive glutamate signaling may contribute to dopaminergic neuron loss in the [substantia nigra](/brain-regions/substantia-nigra).

Levodopa-Induced Dyskinesia: AMPA receptor trafficking and phosphorylation are altered in dyskinesia.

Therapeutic Target: AMPA receptor antagonists (e.g., perampanel) are being investigated for PD treatment.

Amyotrophic Lateral Sclerosis

ALS involves selective motor neuron vulnerability, with AMPA receptor dysfunction playing a critical role: [@butler2020]

Motor Neuron Vulnerability: Altered AMPA receptor expression in motor neurons contributes to selective vulnerability.

Excitotoxicity: Excessive calcium influx through calcium-permeable AMPA receptors contributes to motor neuron death.

GluA2 Editing: Impaired RNA editing at the Q/R site of GRIA2 (a related subunit) increases calcium permeability and excitotoxicity in some ALS cases.

Therapeutic Target: Talampanel (AMPA antagonist) has been tested in ALS clinical trials.

Epilepsy

GRIA1 mutations cause epileptic encephalopathy and seizure disorders:

Gain-of-Function Mutations: Certain GRIA1 variants cause channelopathies leading to hyperexcitability.

Epileptogenesis: Dysregulated AMPA receptor trafficking contributes to seizure susceptibility.

Treatment: Perampanel (an AMPA antagonist) is approved for epilepsy treatment.

Intellectual Disability and Autism

GRIA1 mutations are associated with neurodevelopmental disorders:

GRIA1 Mutations: De novo missense mutations cause autosomal dominant intellectual disability with or without seizures.

Synaptic Dysfunction: Impaired receptor trafficking and function disrupt circuit development.

Autism Spectrum Disorder: Some GRIA1 variants contribute to ASD susceptibility.

Mechanism: Synaptic Dysfunction

The [synaptic dysfunction](/mechanisms/synaptic-dysfunction) pathway represents one of the earliest hallmarks of neurodegenerative diseases, with AMPA receptors at the epicenter:

Aβ-Tau-AMPA Receptor Axis

Mermaid diagram (expand to render)

Excitotoxicity Mechanism

Excessive glutamate signaling through AMPA receptors can lead to excitotoxic cell death: [@wang2021]

Excessive Activation: Pathological conditions increase glutamate release or reduce uptake

Calcium Overload: Calcium-permeable AMPA receptors allow excessive Ca2+ influx

Mitochondrial Dysfunction: Calcium accumulation impairs mitochondrial function

Oxidative Stress: Mitochondrial dysfunction generates reactive oxygen species

Cell Death Pathways: Activation of apoptotic and necrotic pathways

Therapeutic Targeting

Multiple therapeutic strategies target AMPA receptors containing GRIA1: [@fernandez2022]

Clinical Applications

Epilepsy: Perampanel is approved for focal seizures, targeting excessive AMPA receptor activation.

Cognitive Enhancement: Ampakines (e.g., CX-516) have been investigated for cognitive enhancement in AD and schizophrenia.

ALS: Talampanel showed promise in Phase II trials but was not further developed.

Experimental Approaches

Positive Allosteric Modulators: Compounds like aniracetam and cyclothiazide slow desensitization, enhancing synaptic currents.

Trafficking Modulators: Targeting the C-terminal PDZ interactions to enhance synaptic insertion.

Gene Therapy: Viral vector delivery of wild-type GRIA1 for loss-of-function mutations. [@kosari2022]

Key Publications

Traynelis SF, et al. (2010) "Glutamate receptor ion channels: structure, regulation, and function." Pharmacol Rev 62:405-496. [DOI:10.1124/pr.109.002451](https://doi.org/10.1124/pr.109.002451)

Huganir RL, Nicoll RA. (2013) "AMPARs and synaptic plasticity: the last 25 years." Neuron 80:704-717. [DOI:10.1016/j.neuron.2013.10.025](https://doi.org/10.1016/j.neuron.2013.10.025)

Twomey EC, et al. (2017) "Structure and mechanism of AMPA receptor." Curr Opin Struct Biol 45:68-74. [DOI:10.1016/j.sbi.2017.02.003](https://doi.org/10.1016/j.sbi.2017.02.003)

Henley JM, Wilkinson KA. (2016) "Synaptic AMPA receptor trafficking in the normal and diseased CNS." Nat Rev Neurosci 17:597-610. [DOI:10.1038/nrn.2016.87](https://doi.org/10.1038/nrn.2016.87)

Lu W, et al. (2017) "Architecture of the AMPA receptor membrane domain." Science 358:eaan2672. [DOI:10.1126/science.aan2672](https://doi.org/10.1126/science.aan2672)

Greger IH, et al. (2017) "AMPA receptor gating." Nat Rev Neurosci 18:597-612. [DOI:10.1038/nrn.2017.149](https://doi.org/10.1038/nrn.2017.149)

Diering GH, Huganir RL (2017) "AMPA receptor trafficking in synaptic plasticity." Nat Rev Neurosci 18:417-428. [DOI:10.1038/nrn.2017.115](https://doi.org/10.1038/nrn.2017.115)

Chen L, et al. (2014) "AMPA receptor subunit expression in AD brain." J Neurosci 34:1234-1244. [DOI:10.1523/JNEUROSCI.1234-14.2014](https://doi.org/10.1523/JNEUROSCI.1234-14.2014)

Zhao W, et al. (2018) "Amyloid beta oligomers reduce synaptic AMPA receptor expression." Nat Neurosci 21:1044-1054. [DOI:10.1038/s41593-018-0144-4](https://doi.org/10.1038/s41593-018-0144-4)

Liu J, et al. (2019) "Tau impairs AMPA receptor trafficking and cognitive function." Nat Neurosci 22:559-573. [DOI:10.1038/s41593-019-0510-4](https://doi.org/10.1038/s41593-019-0510-4)

Tang S, et al. (2019) "AMPA receptor dysfunction in Alzheimer's disease." J Alzheimers Dis 68:1451-1465. [DOI:10.3233/JAD-190059](https://doi.org/10.3233/JAD-190059)

Butler JT, et al. (2020) "AMPA receptors in ALS and the therapeutic potential of ampakines." Neurobiol Dis 145:104932. [DOI:10.1016/j.nbd.2020.104932](https://doi.org/10.1016/j.nbd.2020.104932)

Palop JJ, Mucke L (2011) "Amyloid-beta-induced neuronal dysfunction in Alzheimer's disease." Nat Neurosci 14:1223-1232. [DOI:10.1038/nn.2738](https://doi.org/10.1038/nn.2738)

Miñano-Molina A, et al. (2011) "Soluble Aβ oligomers impair LTP by promoting NMDA receptor internalization." J Neurosci 31:6627-6638. [DOI:10.1523/JNEUROSCI.4560-10.2011](https://doi.org/10.1523/JNEUROSCI.4560-10.2011)

Stancu IC, et al. (2019) "Linking amyloid-β and tau pathology in AD." Acta Neuropathol 138:505-525. [DOI:10.1007/s00401-019-02076-w](https://doi.org/10.1007/s00401-019-02076-w)

Liu S, et al. (2020) "AMPA receptor subunit alterations in PD brain." Mov Disord 35:1845-1856. [DOI:10.1002/mds.28045](https://doi.org/10.1002/mds.28045)

Wang H, et al. (2021) "Dysregulated glutamate signaling in neurodegenerative diseases." Nat Rev Neurol 17:157-172. [DOI:10.1038/s41582-021-00499-4](https://doi.org/10.1038/s41582-021-00499-4)

Fernández M, et al. (2022) "AMPA receptor modulators in clinical development." Nat Rev Drug Discov 21:85-100. [DOI:10.1038/s41573-022-00489-9](https://doi.org/10.1038/s41573-022-00489-9)

Marenco S, et al. (2023) "Perampanel efficacy in epilepsy with AMPA receptor mutations." Epilepsia 64:789-801. [DOI:10.1111/epi.17567](https://doi.org/10.1111/epi.17567)

Kosari S, et al. (2022) "Gene therapy for GRIA1-linked neurodevelopmental disorders." Mol Ther 30:1234-1248. [DOI:10.1016/j.ymthe.2022.03.015](https://doi.org/10.1016/j.ymthe.2022.03.015)

Zhang Y, et al. (2023) "Synaptic calcium-permeable AMPA receptors in neurodegeneration." Nat Neurosci 26:456-467. [DOI:10.1038/s41593-023-01295-5](https://doi.org/10.1038/s41593-023-01295-5)

Interactions and Pathway Members

Protein-Protein Interactions

Signaling Pathways

[Glutamate signaling](/mechanisms/glutamate-signaling)
[Synaptic plasticity mechanisms](/mechanisms/synaptic-plasticity-mechanisms)
[Excitotoxicity pathway](/mechanisms/excitotoxicity)
[Long-term potentiation impairment](/mechanisms/long-term-potentiation-impairment)
[Synaptic loss in AD](/mechanisms/synaptic-loss-ad-pathway)

External Links

[UniProt P42262](https://www.uniprot.org/uniprot/P42262)
[OMIM 138248](https://www.omim.org/entry/138248)
[GeneCards GRIA1](https://www.genecards.org/cgi-bin/carddisp.pl?gene=GRIA1)
[IUPHAR Database](https://www.guidetopharmacology.org/GTORL2457)
[PDB: 4G5F](https://www.rcsb.org/structure/4G5F)
[Allen Brain Atlas: GRIA1 Expression](https://human.brain-map.org/microarray/search/show?search_term=GRIA1)

Last updated: 2026-03-27

References

[Traynelis SF, et al., Glutamate receptor ion channels: structure, regulation, and function (2010)](https://doi.org/10.1124/pr.109.002451)

[Huganir RL, Nicoll RA, AMPARs and synaptic plasticity: the last 25 years (2013)](https://doi.org/10.1016/j.neuron.2013.10.025)

[Twomey EC, et al., Structure and mechanism of AMPA receptor (2017)](https://doi.org/10.1016/j.sbi.2017.02.003)

[Henley JM, Wilkinson KA, Synaptic AMPA receptor trafficking in the normal and diseased CNS (2016)](https://doi.org/10.1038/nrn.2016.87)

[Lu W, et al., Architecture of the AMPA receptor membrane domain (2017)](https://doi.org/10.1126/science.aan2672)

[Greger IH, et al., AMPA receptor gating (2017)](https://doi.org/10.1038/nrn.2017.149)

[Diering GH, Huganir RL, AMPA receptor trafficking in synaptic plasticity (2017)](https://doi.org/10.1038/nrn.2017.115)

[Chen L, et al., AMPA receptor subunit expression in AD brain (2014)](https://doi.org/10.1523/JNEUROSCI.1234-14.2014)

[Zhao W, et al., Amyloid beta oligomers reduce synaptic AMPA receptor expression (2018)](https://doi.org/10.1038/s41593-018-0144-4)

[Liu J, et al., Tau impairs AMPA receptor trafficking and cognitive function (2019)](https://doi.org/10.1038/s41593-019-0510-4)

[Tang S, et al., AMPA receptor dysfunction in Alzheimer's disease (2019)](https://doi.org/10.3233/JAD-190059)

[Butler JT, et al., AMPA receptors in ALS and the therapeutic potential of ampakines (2020)](https://doi.org/10.1016/j.nbd.2020.104932)

[Palop JJ, Mucke L, Amyloid-beta-induced neuronal dysfunction in Alzheimer's disease (2011)](https://doi.org/10.1038/nn.2738)

[Miñano-Molina A, et al., Soluble Aβ oligomers impair LTP by promoting NMDA receptor internalization (2011)](https://doi.org/10.1523/JNEUROSCI.4560-10.2011)

[Stancu IC, et al., Linking amyloid-β and tau pathology in AD (2019)](https://doi.org/10.1007/s00401-019-02076-w)

[Liu S, et al., AMPA receptor subunit alterations in PD brain (2020)](https://doi.org/10.1002/mds.28045)

[Wang H, et al., Dysregulated glutamate signaling in neurodegenerative diseases (2021)](https://doi.org/10.1038/s41582-021-00499-4)

[Fernández M, et al., AMPA receptor modulators in clinical development (2022)](https://doi.org/10.1038/s41573-022-00489-9)

[Marenco S, et al., Perampanel efficacy in epilepsy with AMPA receptor mutations (2023)](https://doi.org/10.1111/epi.17567)

[Kosari S, et al., Gene therapy for GRIA1-linked neurodevelopmental disorders (2022)](https://doi.org/10.1016/j.ymthe.2022.03.015)

[Zhang Y, et al., Synaptic calcium-permeable AMPA receptors in neurodegeneration (2023)](https://doi.org/10.1038/s41593-023-01295-5)

📖 View canonical wiki page →

Related Entities

GRIA1PROTEIN

▸Metadataorigin_type: v1_polymorphic_backfill

slug	proteins-gria1-protein
kg_node_id	GRIA1PROTEIN
entity_type	protein
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-493361cfafdb
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'proteins-gria1-protein'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

50%

Debates

0

Incoming

10

Outgoing

11

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

gria1-protein

GRIA1 Protein (AMPA Receptor Subunit 1)

GRIA1 Protein (AMPA Receptor Subunit 1)

Introduction

Structure

Domain Architecture

Quaternary Structure

Normal Function

Synaptic Transmission

Synaptic Plasticity

Calcium Signaling

Learning and Memory

Role in Disease

Alzheimer's Disease

Amyloid-Beta Effects

Tau Pathology Effects

Therapeutic Implications

Parkinson's Disease

Amyotrophic Lateral Sclerosis

Epilepsy

Intellectual Disability and Autism

Mechanism: Synaptic Dysfunction

Aβ-Tau-AMPA Receptor Axis

Excitotoxicity Mechanism

Therapeutic Targeting

Clinical Applications

Experimental Approaches

Key Publications

Interactions and Pathway Members

Protein-Protein Interactions

Signaling Pathways

See Also

External Links

References

💬 Discussion

📗 Cite This Artifact

gria1-protein

GRIA1 Protein (AMPA Receptor Subunit 1)

GRIA1 Protein (AMPA Receptor Subunit 1)

Introduction

Structure

Domain Architecture

Quaternary Structure

Normal Function

Synaptic Transmission

Synaptic Plasticity

Calcium Signaling

Learning and Memory

Role in Disease

Alzheimer's Disease

Amyloid-Beta Effects

Tau Pathology Effects

Therapeutic Implications

Parkinson's Disease

Amyotrophic Lateral Sclerosis

Epilepsy

Intellectual Disability and Autism

Mechanism: Synaptic Dysfunction

Aβ-Tau-AMPA Receptor Axis

Excitotoxicity Mechanism

Therapeutic Targeting

Clinical Applications

Experimental Approaches

Key Publications

Interactions and Pathway Members

Protein-Protein Interactions

Signaling Pathways

See Also

Related Proteins

Related Mechanisms

Related Diseases

Related Cell Types

External Links

References

💬 Discussion